Hydroxamate triterpenoid derivatives
Triterpenoid derivatives and compositions comprising said triterpenoids derivatives of Formula (I) are described, wherein R═—C(O)NHOH. Said triterpenoids and compositions show capacity to bind PHD2, stabilize HIF-1α and HIF-2α proteins, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, show neuroprotective activity in vitro and in vivo, antidiabetic activity and reduce the levels of lipids in vivo, and increase the plasma levels of Erythropoietin in vivo. The triterpenoid derivatives described act also in a selective manner and do not induce Nrf2 activation, NF-κB inhibition, STAT3 inhibition, and TGR5 activation, which are known activities of the natural triterpenoid precursors. Said triterpenoid derivatives are useful in the treatment of conditions and diseases which are responsive to HIF activation such as stroke, cerebral palsy, traumatic injuries and neurodegenerative diseases; and also IBD, myocardial ischaemia-reperfusion injury, acute lung injury, diabetic and chronic wounds, organ transplantation, acute kidney injury or arterial diseases.
1. A triterpene derivative of Formula (Ia) or stereoisomers, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof,
wherein independently,
A-B is a single carbon-carbon bond or a double carbon-carbon bond;
B is a methylene (—CH 2 —), an olefin methine (═CH—), a hydroxymethine [—CH(OH)—], or a hydroxylated olefin carbon [—C(OH)═];
B-C is a single carbon-carbon bond or a double carbon-carbon bond; or is part of a heterocyclic ring comprising one or more heteroatoms wherein at least one of said heteroatoms is nitrogen; and wherein said heterocyclic ring is a five-membered ring comprising one nitrogen and one oxygen;
C is a hydroxymethine [—CH(OH)—], an acyloxymethine [—CH(OCOR′)—], an olefin methine (═CH—), a carbonyl [—C(═O)—], an oxime [—C(═N—OH)—] or an hydrazone [—C(═N—NH 2 )—], wherein R′ is methyl;
D-E is a single or a double carbon-carbon bond;
F is F 1a , F 2a or F 3a ;
G is a methylene (—CH 2 —) or a carbonyl [—C(═O)—]; and
R is a hydroxamate group (—CONHOH);
and wherein,
when C is an acyloxymethine [—CH(OCOR′)—], the triterpene derivative of Formula (Ia) is
when B is a methylene (—CH 2 —), C is a hydroxymethine [—CH(OH)—], D-E is a double carbon-carbon bond, G is a methylene (—CH 2 —) and R is a hydroxamate (—CONHOH), F is F 3a ;
when B is a methylene (—CH 2 —), C is a hydroxymethine [—CH(OH)—], D-E is a single carbon-carbon bond, G is a methylene (—CH 2 —) and R is a hydroxamate (—CONHOH), F is F 1a or F 2a ;
when B is a methylene (—CH 2 —), C is an oxime [—C(═N—OH)—], D-E is a double carbon-carbon bond, G is a methylene (—CH 2 —) and R is a hydroxamate (—CONHOH), F is F 1a or F 3a .
2. The triterpene derivative according to claim 1 , wherein said triterpene derivative is selected from the group consisting of:
3. A compound selected from the group consisting of XVIII and XIX:
4. A pharmaceutical composition comprising at least one triterpene derivative of Formula (Ia) of claim 1 as a first active ingredient and at least one excipient or carrier.
5. A method of treating a condition or disease responsive to the activation of a HIF pathway, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of the triterpene derivative of claim 1 .
6. The method of claim 5 , wherein the condition or disease responsive to the activation of the HIF pathway is selected from the group consisting of stroke, cerebral palsy, traumatic injuries and neurodegenerative diseases.
7. The method of claim 5 , wherein the condition or disease responsive to the activation of the HIF pathway is selected from the group consisting of IBD, myocardial ischaemia-reperfusion injury, acute lung injury, diabetic and chronic wounds, organ transplantation, acute kidney injury and arterial diseases.
8. The method of claim 5 , wherein the condition or disease responsive to the activation of the HIF pathway is diabetes, hyperlipidemia or hypertriglyceridemia.
9. The method, according to claim 5 , wherein said method produces an increase in the erythropoietin plasma levels.
10. A method of treating a condition or disease wherein the treatment of said condition or disease benefits from HIF-1α or HIF-2α activation, the method comprising administering to a subject in need thereof a triterpene derivative of Formula (I) or, stereoisomers, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof,
wherein independently,
A-B is a single carbon-carbon bond or a double carbon-carbon bond;
B is a methylene (—CH 2 —), an olefin methine (═CH—), a hydroxymethine [—CH(OH)—], or a hydroxylated olefin carbon [—C(OH)═];
B-C is a single carbon-carbon bond or a double carbon-carbon bond; or is part of a heterocyclic ring comprising one or more heteroatoms wherein at least one of said heteroatoms is nitrogen; and wherein said heterocyclic ring is a five membered ring comprising one nitrogen and one oxygen;
C is a hydroxymethine [—CH(OH)—], an acyloxymethine [—CH(OCOR′)—], an olefin methine (═CH—), a carbonyl [—C(═O)—], an oxime [—C(═N—OH)—] or an hydrazone [—C(═N—NH 2 )—], wherein R′ is methyl;
D-E is a single or a double carbon-carbon bond;
F is F 1 , F 2 or F 3 ;
G is a methylene (—CH 2 —) or a carbonyl [—C(═O)—]; and
R is a hydroxamate group (—CONHOH).
11. The method according to claim 10 , wherein said triterpene derivative is selected from the group consisting of:
12. The method of claim 10 , wherein said condition or disease is selected from the group consisting of stroke, cerebral palsy, traumatic injuries and neurodegenerative diseases.
13. The method of claim 10 , wherein said condition or disease is selected from the group consisting of IBD, myocardial ischaemia-reperfusion injury, acute lung injury, diabetic and chronic wounds, organ transplantation, acute kidney injury and arterial diseases.
14. The method of claim 10 , wherein the condition or disease is diabetes, hyperlipidemia or hypertriglyceridemia.
15. The method according to claim 10 , wherein said method produces an increase in the erythropoietin plasma levels.
16. The method of claim 10 , wherein said triterpene derivative of Formula (I) is a triterpene derivative of Formula (Ib):
17. The method according to claim 15 , wherein said triterpene derivative is selected from (II), (III), (IV), (V), (VI), (VII), (VIII), (X), (XI), (XII), (XIII), (XIV) or (XV):